IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
enasidenib Sensitive: A1 - Approval
|
enasidenib Sensitive: A1 - Approval
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
venetoclax Sensitive: A2 - Guideline
|
venetoclax Sensitive: A2 - Guideline
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
cytarabine Resistant: B - Late Trials
|
cytarabine Resistant: B - Late Trials
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
temozolomide gel Sensitive: B - Late Trials
|
temozolomide gel Sensitive: B - Late Trials
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
PCV Sensitive: B - Late Trials
|
PCV Sensitive: B - Late Trials
|
IDH2 mutation
|
ALL
|
IDH2 mutation
|
ALL
|
enasidenib Sensitive: B - Late Trials
|
enasidenib Sensitive: B - Late Trials
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
pamiparib Sensitive: C2 – Inclusion Criteria
|
pamiparib Sensitive: C2 – Inclusion Criteria
|
IDH2 mutation
|
Cholangiocarcinoma
|
IDH2 mutation
|
Cholangiocarcinoma
|
dasatinib Sensitive: C2 – Inclusion Criteria
|
dasatinib Sensitive: C2 – Inclusion Criteria
|
IDH2 mutation
|
MDS
|
IDH2 mutation
|
MDS
|
enasidenib Sensitive: C2 – Inclusion Criteria
|
enasidenib Sensitive: C2 – Inclusion Criteria
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
MEN1703 Sensitive: C2 – Inclusion Criteria
|
MEN1703 Sensitive: C2 – Inclusion Criteria
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
AG-881 Sensitive: C2 – Inclusion Criteria
|
AG-881 Sensitive: C2 – Inclusion Criteria
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
TG02 Sensitive: C3 – Early Trials
|
TG02 Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials
|
cytarabine / daunorubicin liposomal formulation Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
venetoclax + enasidenib Sensitive: C3 – Early Trials
|
venetoclax + enasidenib Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
venetoclax + RO5503781 Sensitive: C3 – Early Trials
|
venetoclax + RO5503781 Sensitive: C3 – Early Trials
|
IDH2 mutation
|
Peripheral T-cell Lymphoma
|
IDH2 mutation
|
Peripheral T-cell Lymphoma
|
copanlisib Sensitive: C3 – Early Trials
|
copanlisib Sensitive: C3 – Early Trials
|
IDH2 mutation
|
CMML
|
IDH2 mutation
|
CMML
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
venetoclax + ABBV-621 Sensitive: C3 – Early Trials
|
venetoclax + ABBV-621 Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
CFI-400945 Sensitive: C3 – Early Trials
|
CFI-400945 Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
venetoclax + midostaurin Resistant: C3 – Early Trials
|
venetoclax + midostaurin Resistant: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
venetoclax + gilteritinib Resistant: C3 – Early Trials
|
venetoclax + gilteritinib Resistant: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
venetoclax + sorafenib Resistant: C3 – Early Trials
|
venetoclax + sorafenib Resistant: C3 – Early Trials
|
IDH2 mutation
|
GBM
|
IDH2 mutation
|
GBM
|
temozolomide gel Sensitive: C3 – Early Trials
|
temozolomide gel Sensitive: C3 – Early Trials
|
IDH2 mutation
|
T Cell Non-Hodgkin Lymphoma
|
IDH2 mutation
|
T Cell Non-Hodgkin Lymphoma
|
lenalidomide Resistant: C3 – Early Trials
|
lenalidomide Resistant: C3 – Early Trials
|
IDH2 mutation
|
Anaplastic Astrocytoma
|
IDH2 mutation
|
Anaplastic Astrocytoma
|
PCV Sensitive: C3 – Early Trials
|
PCV Sensitive: C3 – Early Trials
|
IDH2 mutation
|
Sarcoma
|
IDH2 mutation
|
Sarcoma
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
7+3 (DAC) Sensitive: C3 – Early Trials
|
7+3 (DAC) Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
cytarabine + clofarabine Sensitive: C3 – Early Trials
|
cytarabine + clofarabine Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
cytarabine + cladribine Sensitive: C3 – Early Trials
|
cytarabine + cladribine Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
decitabine + clofarabine Sensitive: C3 – Early Trials
|
decitabine + clofarabine Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
decitabine + cladribine Sensitive: C3 – Early Trials
|
decitabine + cladribine Sensitive: C3 – Early Trials
|
IDH2 mutation
|
GBM
|
IDH2 mutation
|
GBM
|
M7824 Sensitive: C3 – Early Trials
|
M7824 Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
CDIAG Sensitive: C3 – Early Trials
|
CDIAG Sensitive: C3 – Early Trials
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
DCAG Sensitive: C3 – Early Trials
|
DCAG Sensitive: C3 – Early Trials
|
IDH2 mutation
|
GBM
|
IDH2 mutation
|
GBM
|
AV-GBM-1 Sensitive: C3 – Early Trials
|
AV-GBM-1 Sensitive: C3 – Early Trials
|
IDH2 mutation
|
Cholangiocarcinoma
|
IDH2 mutation
|
Cholangiocarcinoma
|
AZD0530 Sensitive: D – Preclinical
|
AZD0530 Sensitive: D – Preclinical
|
IDH2 mutation
|
Cholangiocarcinoma
|
IDH2 mutation
|
Cholangiocarcinoma
|
bosutinib Sensitive: D – Preclinical
|
bosutinib Sensitive: D – Preclinical
|
IDH2 mutation
|
Cholangiocarcinoma
|
IDH2 mutation
|
Cholangiocarcinoma
|
ponatinib Sensitive: D – Preclinical
|
ponatinib Sensitive: D – Preclinical
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
APO866 Sensitive: D – Preclinical
|
APO866 Sensitive: D – Preclinical
|
IDH2 mutation
|
Leukemia
|
IDH2 mutation
|
Leukemia
|
venetoclax Sensitive: D – Preclinical
|
venetoclax Sensitive: D – Preclinical
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
NPI-0052 Sensitive: D – Preclinical
|
NPI-0052 Sensitive: D – Preclinical
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
omacetaxine mepesuccinate Sensitive: D – Preclinical
|
omacetaxine mepesuccinate Sensitive: D – Preclinical
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
regorafenib Sensitive: D – Preclinical
|
regorafenib Sensitive: D – Preclinical
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
dactinomycin Sensitive: D – Preclinical
|
dactinomycin Sensitive: D – Preclinical
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
romidepsin Sensitive: D – Preclinical
|
romidepsin Sensitive: D – Preclinical
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
daunorubicin Sensitive: D – Preclinical
|
daunorubicin Sensitive: D – Preclinical
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
teniposide Sensitive: D – Preclinical
|
teniposide Sensitive: D – Preclinical
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
gemcitabine Sensitive: D – Preclinical
|
gemcitabine Sensitive: D – Preclinical
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
paclitaxel Sensitive: D – Preclinical
|
paclitaxel Sensitive: D – Preclinical
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
decitabine Sensitive: D – Preclinical
|
decitabine Sensitive: D – Preclinical
|